Abattis Subsidiary Vergence Announces First Product in Lineup Now Available for Sale

VANCOUVER, BC / ACCESSWIRE / March 3, 2016 / Vergence Sales and Marketing Group, wholly owned subsidiary of Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) (the “Company” or “Abattis”), is pleased to announce the launch and sale of NÖXX BOTANICAL BLENDS™. Each NÖXX product contains PHYTO[NOS]™, a proprietary nitric oxide formula, blended with specific natural fruit and herb extracts that promotes vascular function, immune system function, sexual function and works in tandem with our targeted botanical blends to enhance their focus and effect.

The NÖXX BOTANICAL BLENDS™ line of natural health products were formulated by noted, retired naturopathic doctor and global health ambassador, Brazos Minshew. Brazos brings his decades of naturopathic and product development experiences to create products which address ailments that positively impact our health and well being.

Vergence will release the NÖXX BOTANICAL BLENDS line of products one product at a time. The first to launch, Comfort ™ White Willow Blend, is available for pre-sale now in the United States and is scheduled to be shipped to customers later in March. Comfort™ is an ancient remedy with a modern twist. For thousands of years, Asian physicians trained in Traditional Chinese Medicine have used powerful herbs to improve the comfort of their patients. In North America, the traditional healers of Native cultures used plants to improve the performance of their most valued Tribal Members. We combined the remedies from these two cultures to create the matrix for Comfort™. With the addition of PHYTO[NOS]™, we combined modern ingredients designed to improve circulation with plants combinations to improve performance and reduce discomfort. The general trend in consumers making healthier choices related to dietary options continues to grow. In keeping with that sentiment, we have always tried to create value for our shareholders and those efforts continue.

“We at Abattis are very excited about this first step in the sale of natural health products by Vergence.” Says Bill Fleming, Abattis’ CEO. “With the science divisions of Abattis to support research and development, technologies that will be deployed to establish a base of safe and reliable ingredients and an extensive array of natural product formulations that will be taken to market over time, Abattis is uniquely positioned to foster the development of products that will provide profound health benefits to consumers today and will be further enhanced in future with the addition of innovative, cannabinoid-based ingredients as regulations allow.”

About Vergence Sales and Marketing Group.

Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast growing market for natural, safe and effective natural products that meet unmet wellness needs.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

“Bill Fleming”
Bill Fleming, CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

SOURCE: Abattis Bioceuticals Corp.

ReleaseID: 437455